Extensive and updated reviews on the importance of different immunotherapies for HER2 BC treatment have been recently published elsewhere (see, for instance [99,100,101]); thus, only the most relevant results are briefly mentioned here. The gene discussed is ERBB2; the disease is breast cancer.